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OBJECTIVES This study was designed to analyze the results of fibrinolytic treatment (FT) in a large
single-center group of patients with prosthetic heart valve thrombosis (PHVT).
BACKGROUND Fibrinolytic treatment of PHVT represents an alternative to surgery, but is still controversial
because of the risk of embolism.
METHODS A total of 110 consecutive patients presenting with 127 instances of PHVT received FT
between 1978 and 2001. The diagnosis of PHVT was established mainly by fluoroscopy
and/or echocardiography. The first fibrinolytic agent used was streptokinase (SK) in 49 cases,
urokinase (UK) in 41 cases, and recombinant tissue-type plasminogen activator (rtPA) in 37
cases. A second FT was consecutively infused in 38 patients (30%) and a third FT in 11
others. The efficacy of FT was assessed from hemodynamic parameters derived from
echographic examinations as well as on clinical grounds.
RESULTS Complete resolution of hemodynamic abnormalities was seen in 90/127 patients, partial
resolution in 22/127 patients, and no change in 15/127 patients after one or more consecutive
fibrinolytic regimens. When SK or rtPA were used as the first fibrinolytic agent, they
appeared significantly superior to UK in terms of valve reopening. Fifteen patients died.
Severe hemorrhagic complications were observed in six patients. Nineteen documented
embolic events occurred during FT. Finally, PHVT recurred in 24 patients, 17 of whom were
retreated with lytic agents.
CONCLUSIONS These results indicate that FT is effective in most cases of PHVT, regardless of prosthesis or
site involved. However, embolism, hemorrhage, and death were not uncommon after lytic
therapy of left-sided PHVT, limiting its application to patients at high risk with alternative
treatment. (J Am Coll Cardiol 2003;41:653–8) © 2003 by the American College of
Cardiology Foundation
Thromboembolic complications remain a frequent cause of
morbidity and mortality in patients with a mechanical
prosthetic heart valve. The reported incidence of such
complications ranges from 0.03% to 4.3% patient-years,
depending on the generation and the thrombocity of the
prosthesis used, the location of the valve, and the quality of
the anticoagulation (1–6).
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Prosthetic cardiac valve thrombosis (PHVT) is a serious
complication associated with a high mortality, and requires
immediate diagnosis and treatment. Optimal management
of patients with obstructive prosthetic thrombosis remains
controversial, although surgery is usually favored (7).
Fibrinolysis treatment (FT) has been proposed as an
alternative since 1971 (8–12), and in the 1980s, because of
the risk of surgery in such situations, FT was proposed by
many authors as the first line of therapy for PHVT. The
results were encouraging. However, studies on large series
showed a real risk of emboli, with possible permanent
clinical damage (11,12).
We report here a single-center retrospective study of all
cases of FT for PHVT, in order to better define the initial
efficacy and safety of such treatment.
METHODS
Patients. Patients were collected from the databases of the
echocardiographic laboratory, the intensive care unit, and
the surgical department of our institution, whose catchment
area includes the southwest of France (three million inhab-
itants).
Between 1978 and 2001, we documented 127 PHVT
episodes (110 patients) treated with fibrinolytic agents.
The advent of improved surgical techniques (13,14),
along with the development of new and more accurate
diagnostic investigations (15–19) of thrombotic material,
such as transesophageal echocardiography (TEE), has led to
a fall in FT for PHVT in our institution over the past
decade. Patients with large atrial clots detected by TEE
were usually excluded from thrombolysis (Fig. 1).
There were 70 women (63.6%) and 40 men (36.4%) in
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the study group. The mean age was 57  17 years (range 2
to 86 years). The mean time between PHV implantation
and the thrombotic episode was 4.3  4.2 years (range 14
days to 18 years).
Thrombosed valves comprised 79 (62%) bileaflet valves
(47 Saint Jude, 22 Duromedics, 10 Carbomedics) and 48
(38%) tilting disc prostheses (41 Bjo¨rk Shiley, 7 Kaster
Omniscience). They included 79 mitral, 46 aortic, 1 tricuspid,
and 1 mitral-tricuspid sites. Thrombosis was obstructive in 115
cases (91%) and nonobstructive in 12 cases (9%). Nearly half
the patients (48%) were not receiving adequate anticoagulant
therapy at the time of diagnosis of the thrombosis.
Clinical data. The main clinical signs at the time of
thrombosis were dyspnea, congestive heart failure, and
systemic embolism. In 49 cases (38.6%), massive obstruction
of the prosthesis led to acute or subacute pulmonary edema
and, in some cases, low cardiac output (New York Heart
Association [NYHA] functional class IV). Forty-one pa-
tients (32.3%) were in NYHA functional class III and 37
(29.2%) in class II or I. Massive obstruction (NYHA
functional class IV) was more frequent with the disc
prostheses (26/48, 54%) than with the bileaflet prostheses
(23/79, 29%) (p  0.005). An early systemic embolic
episode occurred in 28 cases (21%) before admission or FT.
Diagnostic procedures. The clinical suspicion of PHVT
was confirmed by complementary investigations in all pa-
tients, except two who were critically ill. Seven patients were
catheterized initially. Because poppets impervious to X-rays
are used by manufacturers, cinefluoroscopy was generally
employed (n  100). Currently, Doppler transthoracic
echocardiography (TTE) is usually performed in such situ-
ations (n  115), sometimes backed up by TEE (n  49).
Fibrinolytic regimens. In all cases, FT was chosen in
agreement with the surgical team, particularly in those
patients for whom surgery was contraindicated. Various
fibrinolytic regimens were used, depending on the availabil-
ity of the different agents.
STREPTOKINASE (SK) (STREPTASE, HOESCHT LABORATO-
RIES, GERMANY). Classical regimen: loading dose 500,000 IU
in 20 min followed by 1,500,000 IU for 10 h (children’s
loading dose 2,000 IU/kg, then 1,200 IU/h for 48 h)
without heparin. Accelerated protocol: loading dose 500,000
IU in 20 min, then 1,500,000 IU over 60 min without
heparin. This recent option was rarely used in our series.
UROKINASE (UK) (UROKINASE, CHOAY LABORATORIES,
FRANCE). High dose: 4,500 IU/kg/h for 12 h without heparin.
Low dose: 2,000 IU/kg/h associated with heparin for 24 h.
RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (rtPA)
(BOERINGHER INGELHEIM, GERMANY). High dose (100 mg):
loading dose 10 mg, followed by 90 mg for 90 min or for 3 h
without heparin. Low dose (50 mg): loading dose 20 mg then
10 mg/h for 3 h without heparin.
A combination of two or more fibrinolytic agents was
used in one-third of the patients, particularly with SK and
UK, when the first course failed or results were incomplete
(Table 1).
Heparin infusion was usually introduced after FT, when
fibrinogen level was higher than 0.5 g/l. Heparin infusion to
obtain a partial thromboplastin time at least equal to the
control value was continued for one week and then replaced
by warfarin treatment adjusted to obtain optimal prothrom-
Abbreviations and Acronyms
FT  fibrinolysis treatment
NYHA  New York Heart Association
PHVT  prosthetic heart valve thrombosis
rtPA  recombinant tissue-type plasminogen activator
SK  streptokinase
TEE  transoesophageal echocardiography
TTE  transthoracic echocardiography
UK  urokinase
Figure 1. Fibrinolysis of prosthetic valve thrombosis: distribution of cases over time (1978 to 2001) in our institution.
Table 1. Fibrinolytic Regimen
SK
Group
(n  49)
UK
Group
(n  41)
rtPA
Group
(n  37) Total
Single 34 24 30 88
Combined 15 17 7 39
rtPA  recombinant tissue-type plasminogen activator; SK  streptokinase; UK 
urokinase.
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bin time and international normalized ratio. Low molecular
heparin was never used.
Evaluation of efficacy. Efficacy of FT was evaluated from
the clinical data and the TTE and cinefluoroscopic findings.
Although we usually observed a rapid improvement in
clinical status, FT was continued until the TTE and/or
cinefluoroscopic data became normal.
We defined success as:
1. Full: hemodynamic normalization confirmed by cine-
fluoroscopy (normal mobility of tilting disks) or TTE/
TEE data (normalization of transprosthetic gradient and
valve area, normal mobility of leaflet).
2. Incomplete: significant clinical improvement without
complete recovery of disc or leaflet motion on fluoros-
copy and/or TTE.
3. Failure: no clinical improvement, in many cases associ-
ated with death or complications.
4. In some cases, FT succeeded in hemodynamic terms, but
failed because of severe complications. These patients
were classified as success with complications.
Statistical analysis. The relations among the fibrinolytic
agents, the valve type, and the efficacy of FT were compared
using the Pearson chi-squared test (with Yates correction
for small groups).
RESULTS
Efficacy of thrombolytic treatment. OVERALL EFFICACY
(FIG. 2). Full success with one or more consecutive fibrino-
lytic regimens was obtained in 90 out of 127 cases (70.9%):
37/46 (80%) aortic valve, 52/80 (65%) mitral valve, and 2/2
tricuspid prostheses (100%). Fibrinolytic therapy was more
efficient in aortic prosthesis thrombosis than in mitral
prosthesis thrombosis (p  0.07). Full success was obtained
in 62 patients (48%) with a single fibrinolytic agent, and in
28 other patients using a second or a third fibrinolytic agent
consecutively (combined therapy). Combined therapy ap-
peared to be more effective on the aortic site (38/46 82.6%)
than the mitral (52/80 65%) site (p  0.02). Incomplete
success was obtained in 22 patients (17.3%), usually neces-
sitating surgery. Failure was noted in 15 patients (11.8%),
usually leading to surgery.
EFFICACY ACCORDING TO FIBRINOLYTIC REGIMEN (FIG. 3).
A single fibrinolytic regimen was used in 88 patients and
combined therapy in 39 patients.
In the patients treated by SK as first agent (SK group),
28/49 (57%) had full success with a single agent; 14 other
patients (29%) had full success using one or two other fibrino-
lytic agents (combined therapy). Incomplete success or failure
was observed in only seven patients with SK (14%).
In the patients treated by UK as first agent (UK group),
15/41 (36.6%) had full success with the single agent, and 9
other patients (22%) had full success using combined
Figure 2. Efficacy of fibrinolysis of prosthetic valve thrombosis.
Figure 3. Efficacy according to fibrinolytic agent: on the left, after the first single fibrinolysis treatment (FT); on the right, after complementary FT
(combined therapy). rtPA  recombinant tissue-type plasminogen activator; SK  streptokinase; UK  urokinase.
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therapy. An incomplete success or a failure was observed in
17 patients (41.4%) treated with UK.
In the patients treated by rtPA as first agent (rtPA
group), 21/37 (43%) had full success with a single agent, and
4 others had full success with combined therapy. An
incomplete success or a failure was observed in 13 patients
(33%) treated with rtPA.
As first fibrinolytic agent, SK or rtPA appeared signifi-
cantly superior to UK in terms of valve reopening: SK 
57%, rtPA 43%, UK 36.6%. Combined therapy improved
the results of FT in all groups; however, no significant
difference was observed between the three groups.
Analysis of the global results in the three groups showed
that full success was obtained in 42/49 (86%) of the cases in
the SK group, in 24/41 (59%) in the UK group, and in
25/37 (68%) in the rtPA group. With respect to valve
reopening, the SK group thus appeared to be more efficient
than the rtPA group or UK group.
EFFICACY ACCORDING TO FUNCTIONAL CLASSES. Fibrino-
lytic therapy improved the clinical status in all functional
classes, but full success was higher in patients in NYHA
functional classes I and II than in patients in NYHA
functional classes III and IV (30/37 [81%] vs. 60/90 [67%],
p  0.10).
EFFICACY ACCORDING TO PROSTHETIC VALVE TYPE. There
was no significant difference in efficacy of FT between the
tilting discs or the bileaflet valves (38/48 [79%] vs. 53/79
[67%], p  0.14) (Table 2).
EFFICACY ON INITIAL OR RECURRENT THROMBOSIS. Sev-
enteen recurrent thrombotic episodes were treated with
fibrinolysis. There was no significant difference in efficacy of
FT between the first episode (71%) and a recurrence (75%).
Complications of fibrinolysis. Complications were ob-
served in 32 patients (25.2%). Major bleeding occurred in
six patients (4.7%): two brain hemorrhage (one death) and
four peripheral hemorrhage (two deaths).
Systemic embolisms were observed in 19 patients (15%):
transient ischemic attack (n  6), stroke (n  8) compli-
cated by death in 7 cases because of secondary cerebral
hemorrhage in 4 patients, peripheral embolism (n  5)
completely medically treated in 4 patients, and by embolec-
tomy in 1 patient.
Death occurred in 15 patients (11.8%), attributable to a
primary failure of FT in 5 cases and to complications in 10
cases (7 strokes, 3 hemorrhages).
There was no correlation between NYHA functional
class and the occurrence of hemorrhage or embolism.
However, mortality was significantly higher in patients in
NYHA functional classes III and IV (n  14) than in
NYHA functional classes I and II (n 1) (p 0.04). There
was no correlation between the number of regimens and the
incidence of complications (emboli, hemorrhage, death).
There were no significant differences in type of complication
(emboli, hemorrhage, death) among the different agents
employed (SK, rtPA, or UK).
The incidence of complications in general was higher in
patients in NYHA functional classes III and IV (25/90,
28%) than in patients in NYHA functional classes I and II
(6/37, 16%).
Risk stratification using TEE. Forty-nine patients with
PHVT benefited from TEE followed by fibrinolysis from
1989 to 2001. The majority of cases involved the mitral
valve (37 mitral, 11 aortic, 1 mitral-tricuspid). Forty-one
cases were obstructive and eight were nonobstructive. The
overall hemodynamic success rate was 71%; complications
occurred in eight patients (18%). There was no significant
correlation between the size of the thrombus and the
occurrence of embolic events, although a huge thrombus
imaged by TEE was associated with failure of FT or
complications (p  0.03).
Subsequent treatment and outcome. SURGERY. Twenty-
five patients underwent surgery after thrombolysis because
of incomplete success or failure of FT in all cases but two
(systematic surgery).
RECURRENCE. Recurrence was noted in 24 cases (18.9%)
with a mean interval of 2.06 years (range 3 months to 7
years). In two pregnant women there were two recurrences.
Sixteen patients were treated with FT with a full success
rate of 75%, five underwent surgery, two were treated with
heparin, and one died soon after admission to hospital.
DISCUSSION
Thrombosis is a serious complication of prosthetic heart
valve replacement and incurs a high mortality. Early diag-
nosis of obstructive thrombosis is paramount in optimizing
management.
We report here a single-center study of 127 instances of
PHVT treated with fibrinolysis over a 22-year period. The
efficacy of FT was assessed by well-established hemody-
namic parameters derived from echographic and cinefluo-
roscopic examinations as well as by clinical evaluation. After
one or several consecutive FT regimens, we observed com-
plete resolution of hemodynamic abnormalities in 70.9% of
the cases, partial resolution in 17.3%, and no change in
11.8%. Severe hemorrhagic complications were observed in
4.7% of the cases, with 19 (15%) documented embolic
events. A number of patients died (11.8%), either from low
cardiac output or from complications. In 18.9% of the cases,
there was a recurrence.
Table 2. Efficacy According to the prosthetic Value Type
Tilting
Disc
(n  48)
Bileaflet
Valve
(n  79)
p
Value
Full success 77% (37) 67 (%) 0.23
Incomplete success 15% (7) 19% (15) NS
Failure 8% (4) 14% (11) 0.34
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Management of PHVT is Still Controversial.
Thrombectomy or valve replacement are the treatments of
choice for PHVT (7). However, mortality rates are high,
ranging from 8% to 20% for urgent cases and 37% to 54%
for critically ill patients, depending on the clinical status.
However, in a study of 100 patients undergoing surgical
treatment for obstruction of various types of currently used
mechanical valves, Deviri et al. (13) reported an early
mortality rate of 12.3%. The perioperative mortality rate
was 17.5% in patients in NYHA functional class IV, and
only 4.7% in NYHA functional classes I to III.
Fibrinolysis treatment represents a very interesting alter-
native to surgery; it is easy to perform, but is still contro-
versial because of the risk of embolism.
The recent review of Lengyel et al. (20) of 200 published
reports of left-sided prosthetic heart valve thrombolysis
showed an 82% initial success rate, an overall thromboem-
bolism rate of 12%, and a mortality rate of 10%. This
consensus conference indicates that FT of left-sided PVT is
acceptable for critically ill patients in whom surgical inter-
vention carries high risk or in patients with contraindica-
tions to operation. The reasoning against thrombolysis in
patients in NYHA functional classes I or II is based on the
relatively low surgical mortality in this group, as opposed to
the embolic risk of 12% to 17% from thrombolysis.
Our experience is less encouraging than those reported
recently by Lengyel and Vandor (21) from a compilation of
10 studies each reporting data from 16 to 110 patients (515
cases). The overall success rate was 84%, mortality 5%,
major bleeding 3%, systemic embolism 9% (but only 1.5% of
disabling or fatal stroke), and a recurrence rate of 16%.
However, our results are close to those of the recent study
of Gupta et al. (22), who reported a single-center study of
110 consecutive patients. A complete hemodynamic re-
sponse was seen in 81.8%, a partial response in 10%, and
failure in 8.2%. There were 21 (19.1%) embolic episodes
during therapy, including 6 strokes and 25 recurrences
during the follow-up period.
Numerous fibrinolytic protocols have been used over the
past 30 years (10,12,20,23–28). So far there is a lack of
consensus on the optimal thrombolytic agent and treatment
protocol for PHVT, although most experience has been
accumulated with SK.
In this study, conventional long-course SK or UK pro-
tocols were generally employed as the first line of therapy,
often in combination with a second FT. However, rtPA was
used as the first agent in 37 cases. Our results suggested that
long-course SK is more effective than UK. Recombinant
tissue-type plasminogen activator also appears to be an
effective fibrinolytic agent, although unlike Lengyel et al.
(20), we did not find that rtPA increased embolic risk.
We believe that in critically ill patients, a high-dose,
short-course protocol may be proposed for rapid hemody-
namic improvement, although for patients in a stable
condition conventional long-course fibrinolysis may be both
effective and safe.
Although few reports of successful thrombolysis of left
atrial clots have been published, we think that a large clot
should be ruled out by TEE before instigating FT. Trans-
esophageal echocardiography should be performed in he-
modynamically stable patients if uncertainty remains about
the mechanism and degree of the obstruction. We feel that
FT may be proposed in subacute obstruction after elimina-
tion of a large thrombotic material by TEE (29).
Thrombolysis and surgical treatment have been directly
compared in only one study (30): rtPA treatment was fully
successful without complications in all eight cases of partial
or nonobstruction (NYHA functional class II to III), and
there was one death among 20 surgical patients in NYHA
functional class III to IV. These authors concluded that
thrombolysis was an appropriate treatment in selected cases.
Although evidence-based medicine cannot be used for
this pathology, a general consensus may be reached based on
literature reports (20,21).
Treatment algorithm (Fig. 4). A treatment algorithm is
required to optimize treatment of PHVT. Right-sided
PHVT: Fibrinolysis is the first line of therapy. Left-sided
PHVT: Surgery is usually the treatment of choice of left-
sided prosthetic valves (7), particularly in cases of chronic
obstruction or in cases of early postoperative obstruction.
However, fibrinolysis may be proposed in critically ill
patients with acute obstruction if immediate surgery is not
possible, or if there is a contraindication to surgery (low
cardiac output, respiratory insufficiency, redo surgery). Fi-
brinolysis treatment may also be proposed to clinically stable
patients after elimination by TEE of significant thrombotic
material. Finally, Reddy et al. (25) has suggested that
thrombolysis may represent a valuable alternative in devel-
oping countries with limited resources.
Study limitations. This report analyzes retrospectively our
experience of 127 prosthetic heart valve thromboses, treated
with fibrinolytic agents over the past 22 years. The patients
were selected for FT on the basis of the clinical judgment of
the physicians.
The choice of the fibrinolytic agent was arbitrary, and the
selection criteria of patients for FT were modified as a result
of progress in diagnostic procedures. It is difficult to
compare agents even among themselves, as they correspond
to different generations and periods of utilization. For
Figure 4. Treatment algorithm for left-sided prosthetic heart valve throm-
bosis. TEE  transesophageal echocardiography.
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example, for the rtPA used since 1990 in cases of FT failure,
we chose to operate rather than administer combination FT.
Unfortunately, it is not possible to carry out a prospective
randomized trial comparing FT and surgery, as the number
of cases of PHVT is too small in a single center, and many
factors affect the final therapeutic decision (such as contra-
indications to either surgery or fibrinolysis).
CONCLUSIONS
Valve obstruction is one of the most serious complications
of a mechanical prosthetic valve. Recent studies have
pointed out the variety of anatomical lesions (thrombus,
pannus) and the wide spectrum of clinical presentations.
Furthermore, the advent of new and more accurate diag-
nostic procedures, particularly TEE, enabled us to better
select therapeutic options.
Fibrinolytic therapy is effective in PHVT, and SK and
rtPA appear to be more effective than UK. Fibrinolytic
therapy seems less effective on mitral valves. Major complica-
tions include systemic emboli and death, which are more likely
to occur in patients in NYHA functional class IV. Thrombosis
recurrence is frequent, particularly on mitral valves.
According to American College of Cardiology/American
Heart Association suggestions (7), surgery is the favored
treatment of left-sided PHVT. However, FT may be
justified in cases of tricuspid valve thrombosis and in
selected cases of left-sided PHVT, such as critically ill
patients if immediate surgery is not possible, or in cases
where there are contraindications to surgery (low cardiac
output, respiratory insufficiency, redo surgery).
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